COMMUNIQUÉS West-GlobeNewswire

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/08/2026
MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Sight Sciences Reports Second Quarter 2026 Financial Results
05/08/2026
Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an [...]
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
05/08/2026
Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027 Enrollment also ongoing for the Phase II [...]
Nyxoah Publie ses Résultats Financiers et Opérationnels du Deuxième Trimestre et du Premier Semestre 2026
05/08/2026
INFORMATIONS RÉGLEMENTÉES Nyxoah Publie ses Résultats Financiers et Opérationnels du Deuxième Trimestre et du Premier Semestre 2026 L’exécution commerciale aux États-Unis soutient la dynamique du lancement et se traduit [...]
Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results
05/08/2026
REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2 [...]
PacBio Announces Second Quarter 2026 Financial Results
05/08/2026
MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0 million was driven by [...]
OraSure Announces Second Quarter 2026 Financial Results
05/08/2026
BETHLEHEM, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for [...]
Standard BioTools Reports Second Quarter 2026 Financial Results
05/08/2026
BOSTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026. Recent Highlights: [...]
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
05/08/2026
Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior year Second Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash [...]
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
05/08/2026
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations [...]
PacBio Appoints Mark Van Oene as President and Chief Executive Officer
05/08/2026
Christian Henry to Transition from President and Chief Executive Officer Following Six Years of Leadership; Effective August 5, 2026 MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of [...]
LifeMD Reports Second Quarter 2026 Results
05/08/2026
Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially. [...]
Pennant Reports Second Quarter 2026 Results
05/08/2026
Conference Call and Webcast scheduled for tomorrow, August 6, 2026 at 10:00 am MT EAGLE, Idaho, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
05/08/2026
Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 [...]
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
05/08/2026
WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz ® (aminolevulinic acid hydrochloride) Gel, [...]
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
05/08/2026
– LOQTORZI ® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer – – Projected October [...]
STERIS Announces Financial Results for Fiscal 2027 First Quarter
05/08/2026
Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% Fiscal 2027 first quarter as reported diluted EPS increased to $2.04; adjusted EPS per diluted share increased to $2.59 [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
05/08/2026
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 05 août 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Monthly information on share capital and company voting rights
05/08/2026
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]

Pages